ACADIA Pharmaceuticals to Present at Two Upcoming Virtual Investor Conferences
Get Alerts ACAD Hot Sheet
Join SI Premium – FREE
SAN DIEGO--(BUSINESS WIRE)-- ACADIA Pharmaceuticals Inc. (Nasdaq: ACAD) today announced that it will present at the following two investor conferences:
- 2020 BofA Securities Health Care Conference on Tuesday, May 12, 2020, at 11:00 a.m. Eastern Time.
- 2020 RBC Capital Markets Global Healthcare Conference on Tuesday, May 19, 2020, at 1:55 p.m. Eastern Time.
These conferences will both be held virtually. Live webcasts of ACADIA’s presentations will be accessible on the company’s website, www.acadia-pharm.com, under the investors section and an archived recording will be available on the website for approximately one month following each presentation.
About ACADIA Pharmaceuticals
ACADIA is a biopharmaceutical company focused on the development and commercialization of innovative medicines to address unmet medical needs in central nervous system disorders. ACADIA has developed and commercialized the first and only medicine approved for the treatment of hallucinations and delusions associated with Parkinson’s disease psychosis. ACADIA also has ongoing clinical development efforts in additional areas with significant unmet need, including dementia-related psychosis, major depressive disorder, the negative symptoms of schizophrenia, and Rett syndrome. This press release and further information about ACADIA can be found at: www.acadia-pharm.com.
View source version on businesswire.com: https://www.businesswire.com/news/home/20200505005964/en/
Media Contact:
ACADIA Pharmaceuticals Inc.
Stephanie Fagan
(858) 212-0534
[email protected]
Investor Contact:
ACADIA Pharmaceuticals Inc.
Mark Johnson, CFA
(858) 261-2771
[email protected]
Source: ACADIA Pharmaceuticals Inc.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- ComEd Debuts Mobile Assistance Unit at Waukegan Resource Fair, Bringing On-Site Bill Help Directly to Customers
- Halliburton Announces Dividend
- Orum Therapeutics Announces U.S. FDA Clearance of an IND Application for ORM-1153, a Novel CD123-GSPT1 Degrader-Antibody Conjugate
Create E-mail Alert Related Categories
Business Wire, Press ReleasesRelated Entities
RBC CapitalSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!



Tweet
Share